Efficacy of Panax notoginseng saponins on functional outcome in obese patients with acute ischemic stroke

IF 7.5 2区医学 Q1 CHEMISTRY, MEDICINAL

Journal of Ginseng Research Pub Date : 2026-05-01 Epub Date: 2026-02-06 DOI:10.1016/j.jgr.2026.100991

Sijin Wang , Peipei Du , Longfei Wu , Ziwen Xu , Yixuan Li , Ying Gao , Xunming Ji , Haiqing Song , Chi Zhang

{"title":"Efficacy of Panax notoginseng saponins on functional outcome in obese patients with acute ischemic stroke","authors":"Sijin Wang , Peipei Du , Longfei Wu , Ziwen Xu , Yixuan Li , Ying Gao , Xunming Ji , Haiqing Song , Chi Zhang","doi":"10.1016/j.jgr.2026.100991","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Obesity exacerbates acute ischemic stroke (AIS) outcomes through metabolic dysfunction and chronic inflammation. Although <em>Panax notoginseng</em> saponins (PNS) have demonstrated efficacy in the treatment of AIS in the large-scale PANDA trial (N = 3,072; ChiCTR1800016363), their benefits in patients with obesity specifically, remain unclear. This study aimed to evaluate the effect of PNS on functional outcomes in patients with obesity.</div></div><div><h3>Methods</h3><div>This analysis utilized individual patient data from the PANDA trial. Participants were stratified by body mass index (BMI), waist circumference (WC), and a combination of both metrics. The primary outcome was functional independence, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days. Adjusted odds ratios (aORs) were calculated using multivariable logistic regression.</div></div><div><h3>Results</h3><div>Among 2,779 patients (mean age 60.7 ± 9.3 years), 58.3% were classified as overweight or obese by BMI, and 65% met criteria for abdominal obesity based on WC. PNS significantly improved rates of functional independence at 90 days across overweight (aOR = 2.05; 95% CI: 1.39–3.06), obesity (aOR = 2.18; 95% CI: 1.11–4.41), and abdominal obesity (aOR = 2.37; 95% CI: 1.73–3.28) subgroups. Consistent benefits were observed in patients with abdominal obesity irrespective of BMI category: lower BMI (aOR = 2.45; 95% CI: 1.34–4.61) and higher BMI (aOR = 2.40; 95% CI: 1.64–3.54).</div></div><div><h3>Conclusions</h3><div>These results indicate that PNS may improve 90-day functional outcomes in patients with AIS and obesity, including those with abdominal obesity, warranting further prospective validation.</div></div>","PeriodicalId":16035,"journal":{"name":"Journal of Ginseng Research","volume":"50 3","pages":"Article 100991"},"PeriodicalIF":7.5000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ginseng Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1226845326000175","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Obesity exacerbates acute ischemic stroke (AIS) outcomes through metabolic dysfunction and chronic inflammation. Although Panax notoginseng saponins (PNS) have demonstrated efficacy in the treatment of AIS in the large-scale PANDA trial (N = 3,072; ChiCTR1800016363), their benefits in patients with obesity specifically, remain unclear. This study aimed to evaluate the effect of PNS on functional outcomes in patients with obesity.

Methods

This analysis utilized individual patient data from the PANDA trial. Participants were stratified by body mass index (BMI), waist circumference (WC), and a combination of both metrics. The primary outcome was functional independence, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days. Adjusted odds ratios (aORs) were calculated using multivariable logistic regression.

Results

Among 2,779 patients (mean age 60.7 ± 9.3 years), 58.3% were classified as overweight or obese by BMI, and 65% met criteria for abdominal obesity based on WC. PNS significantly improved rates of functional independence at 90 days across overweight (aOR = 2.05; 95% CI: 1.39–3.06), obesity (aOR = 2.18; 95% CI: 1.11–4.41), and abdominal obesity (aOR = 2.37; 95% CI: 1.73–3.28) subgroups. Consistent benefits were observed in patients with abdominal obesity irrespective of BMI category: lower BMI (aOR = 2.45; 95% CI: 1.34–4.61) and higher BMI (aOR = 2.40; 95% CI: 1.64–3.54).

Conclusions

These results indicate that PNS may improve 90-day functional outcomes in patients with AIS and obesity, including those with abdominal obesity, warranting further prospective validation.

Abstract Image

查看原文本刊更多论文

三七总皂苷对肥胖急性缺血性脑卒中患者功能预后的影响

背景：肥胖通过代谢功能障碍和慢性炎症加剧急性缺血性卒中（AIS）的预后。尽管在大规模PANDA试验中，三七皂苷（PNS）已显示出治疗AIS的疗效（N = 3072; ChiCTR1800016363），但其对肥胖患者的具体益处尚不清楚。本研究旨在评估PNS对肥胖患者功能结局的影响。方法本分析利用PANDA试验的个体患者数据。参与者通过身体质量指数（BMI）、腰围（WC）以及两种指标的组合进行分层。主要终点是功能独立性，定义为90天时修改的Rankin量表（mRS）评分0-2。采用多变量logistic回归计算校正优势比（aORs）。结果2779例患者（平均年龄60.7±9.3岁）中，58.3%的患者BMI为超重或肥胖，65%的患者WC符合腹部肥胖标准。在超重（aOR = 2.05; 95% CI: 1.39-3.06）、肥胖（aOR = 2.18; 95% CI: 1.11-4.41）和腹部肥胖（aOR = 2.37; 95% CI: 1.73-3.28）亚组中，PNS显著提高了90天的功能独立性。无论BMI类别如何，腹部肥胖患者均观察到一致的获益：较低BMI （aOR = 2.45; 95% CI: 1.34-4.61）和较高BMI （aOR = 2.40; 95% CI: 1.64-3.54）。这些结果表明，PNS可以改善AIS合并肥胖患者（包括腹部肥胖患者）90天的功能结局，需要进一步的前瞻性验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Ginseng Research CHEMISTRY, MEDICINAL-INTEGRATIVE & COMPLEMENTARY MEDICINE

CiteScore

11.40

自引率

9.50%

发文量

111

审稿时长

6-12 weeks

期刊介绍： Journal of Ginseng Research (JGR) is an official, open access journal of the Korean Society of Ginseng and is the only international journal publishing scholarly reports on ginseng research in the world. The journal is a bimonthly peer-reviewed publication featuring high-quality studies related to basic, pre-clinical, and clinical researches on ginseng to reflect recent progresses in ginseng research. JGR publishes papers, either experimental or theoretical, that advance our understanding of ginseng science, including plant sciences, biology, chemistry, pharmacology, toxicology, pharmacokinetics, veterinary medicine, biochemistry, manufacture, and clinical study of ginseng since 1976. It also includes the new paradigm of integrative research, covering alternative medicinal approaches. Article types considered for publication include review articles, original research articles, and brief reports. JGR helps researchers to understand mechanisms for traditional efficacy of ginseng and to put their clinical evidence together. It provides balanced information on basic science and clinical applications to researchers, manufacturers, practitioners, teachers, scholars, and medical doctors.